vs
Amesite Inc.（AMST）与CytoMed Therapeutics Ltd（GDTC）财务数据对比。点击上方公司名可切换其他公司
CytoMed Therapeutics Ltd的季度营收约是Amesite Inc.的1.1倍（$115.4K vs $108.0K）
Amesite Inc是一家总部位于美国的教育科技企业，主营人工智能驱动的云学习管理系统与定制化在线学习解决方案，服务覆盖高等院校、企业客户及政府机构，提供个性化技能提升、职业培训与学术课程交付服务。
CytoMed Therapeutics是一家临床阶段生物制药企业，专注于开发同种异体CAR-T细胞疗法，用于治疗血液恶性肿瘤与实体瘤，深耕肿瘤免疫领域，致力于满足全球癌症患者未被满足的临床治疗需求。
AMST vs GDTC — 直观对比
营收规模更大
GDTC
是对方的1.1倍
$108.0K
损益表 — Q2 FY2026 vs Q2 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $108.0K | $115.4K |
| 净利润 | $-732.5K | — |
| 毛利率 | — | — |
| 营业利润率 | -689.7% | — |
| 净利率 | -678.0% | — |
| 营收同比 | 746.8% | — |
| 净利润同比 | 34.7% | — |
| 每股收益（稀释后） | $-0.16 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMSTGDTC
| Q4 25 | $108.0K | — | ||
| Q3 25 | $94.3K | — | ||
| Q2 25 | $55.8K | $115.4K | ||
| Q4 23 | $41.4K | — | ||
| Q3 23 | $63.3K | — | ||
| Q2 23 | $123.0K | — | ||
| Q1 23 | $204.6K | — | ||
| Q4 22 | $237.1K | — |
净利润AMSTGDTC
| Q4 25 | $-732.5K | — | ||
| Q3 25 | $-642.3K | — | ||
| Q2 25 | $-924.0K | — | ||
| Q4 23 | $-905.6K | — | ||
| Q3 23 | $-890.7K | — | ||
| Q2 23 | $-948.5K | — | ||
| Q1 23 | $-928.0K | — | ||
| Q4 22 | $-699.5K | — |
营业利润率AMSTGDTC
| Q4 25 | -689.7% | — | ||
| Q3 25 | -702.2% | — | ||
| Q2 25 | -1538.2% | — | ||
| Q4 23 | -2307.0% | — | ||
| Q3 23 | -1500.0% | — | ||
| Q2 23 | -800.6% | — | ||
| Q1 23 | -462.1% | — | ||
| Q4 22 | -300.2% | — |
净利率AMSTGDTC
| Q4 25 | -678.0% | — | ||
| Q3 25 | -681.1% | — | ||
| Q2 25 | -1657.1% | — | ||
| Q4 23 | -2185.2% | — | ||
| Q3 23 | -1406.4% | — | ||
| Q2 23 | -771.1% | — | ||
| Q1 23 | -453.6% | — | ||
| Q4 22 | -295.0% | — |
每股收益（稀释后）AMSTGDTC
| Q4 25 | $-0.16 | — | ||
| Q3 25 | $-0.14 | — | ||
| Q2 25 | $-0.13 | — | ||
| Q4 23 | $-0.36 | — | ||
| Q3 23 | $-0.35 | — | ||
| Q2 23 | $-0.34 | — | ||
| Q1 23 | $-0.37 | — | ||
| Q4 22 | $-0.28 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.2M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.5M | — |
| 总资产 | $2.0M | — |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AMSTGDTC
| Q4 25 | $1.2M | — | ||
| Q3 25 | $1.8M | — | ||
| Q2 25 | $2.3M | — | ||
| Q4 23 | $3.7M | — | ||
| Q3 23 | $4.6M | — | ||
| Q2 23 | $5.3M | — | ||
| Q1 23 | — | — | ||
| Q4 22 | — | — |
股东权益AMSTGDTC
| Q4 25 | $1.5M | — | ||
| Q3 25 | $2.2M | — | ||
| Q2 25 | $2.7M | — | ||
| Q4 23 | $4.4M | — | ||
| Q3 23 | $5.2M | — | ||
| Q2 23 | $6.1M | — | ||
| Q1 23 | $7.0M | — | ||
| Q4 22 | $7.9M | — |
总资产AMSTGDTC
| Q4 25 | $2.0M | — | ||
| Q3 25 | $2.6M | — | ||
| Q2 25 | $3.1M | — | ||
| Q4 23 | $4.6M | — | ||
| Q3 23 | $5.5M | — | ||
| Q2 23 | $6.3M | — | ||
| Q1 23 | — | — | ||
| Q4 22 | $8.3M | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-621.1K | $-855.3K |
| 自由现金流经营现金流 - 资本支出 | — | $-855.4K |
| 自由现金流率自由现金流/营收 | — | -741.5% |
| 资本支出强度资本支出/营收 | — | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流AMSTGDTC
| Q4 25 | $-621.1K | — | ||
| Q3 25 | $-415.8K | — | ||
| Q2 25 | $-439.4K | $-855.3K | ||
| Q4 23 | $-919.1K | — | ||
| Q3 23 | $-658.8K | — | ||
| Q2 23 | $-665.7K | — | ||
| Q1 23 | $-746.9K | — | ||
| Q4 22 | $-1.0M | — |
自由现金流AMSTGDTC
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-855.4K | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | $-687.3K | — | ||
| Q1 23 | $-749.6K | — | ||
| Q4 22 | — | — |
自由现金流率AMSTGDTC
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -741.5% | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | -558.7% | — | ||
| Q1 23 | -366.4% | — | ||
| Q4 22 | — | — |
资本支出强度AMSTGDTC
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.0% | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | 17.5% | — | ||
| Q1 23 | 1.3% | — | ||
| Q4 22 | 0.0% | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
